According to the American Cancer Society, more than 60,000 new cases of thyroid cancer will be diagnosed in the U.S., and about 1,850 people are expected......
(read more)
September 23 - News - Comments
Blazing. Sizzling. On fire. They all describe Celgene Corporation (NASDAQ:CELG) pretty well these days. With all of the heat generated by this biotech......
(read more)
September 16 - News - Comments
At the moment, there are a multitude of metrics shareholders can use to monitor stocks. A pair of the most useful are hedge fund and insider trading sentiment......
(read more)
September 10 - News - Comments
As fast as we can type this, Phill Gross and Robert Atchinson’s hedge fund, Adage Capital Partners, disclosed ownership of about 3.7 million shares......
(read more)
September 9 - News - Comments
They say that bad news comes in threes. I’m not sure if there’s a similar saying for good news, but for Celgene Corporation (NASDAQ:CELG)......
(read more)
September 5 - News - Comments
Another domino has fallen in the world of biotech. Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals......
(read more)
September 5 - News - Comments
Editor’s Note: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Amgen, Inc. (NASDAQ:AMGN), Onyx Pharmaceuticals, Inc. (......
(read more)
September 5 - News - Comments
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into......
(read more)
September 1 - News - Comments
Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case......
(read more)
August 27 - News - Comments
After a second offer, Amgen, Inc. (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), a maker of drugs to fight cancer among other diseases,......
(read more)
August 27 - News - Comments
As I’m sure you’ve probably heard by now, Amgen, Inc. (NASDAQ:AMGN) agreed to purchase Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) for $125......
(read more)
August 26 - News - Comments
Although we don’t believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes — just in case......
(read more)
August 26 - News - Comments
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals......
(read more)
August 26 - News - Comments
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a buy? In the 21st century investor’s toolkit, there are tons of metrics market participants can......
(read more)
August 26 - News - Comments
Although we don’t believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes — just in case......
(read more)
August 26 - News - Comments
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors: listen up. In the 21st century investor’s toolkit, there are tons of metrics shareholders can use......
(read more)
August 26 - News - Comments
Since the first day of the week can predict the flow of the whole week, it is particularly crucial to focus on Monday news and events. The same thing......
(read more)
August 26 - News - Comments
Should you be crazy about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)? In the financial world, there are dozens of gauges shareholders can use to analyze......
(read more)
August 26 - News - Comments
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc. (NASDAQ:AMGN) that valued the......
(read more)
August 24 - News - Comments
If you were to ask many investors, hedge funds are assumed to be useless, old investment tools of a period lost to current times. Although there are more......
(read more)
August 23 - News - Comments
There’s been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (......
(read more)
August 23 - News - Comments
Earlier this month, biotech powerhouse Celgene Corporation (NASDAQ:CELG) announced that the European Commission approved the combinational therapy of......
(read more)
August 22 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling......
(read more)
August 19 - News - Comments
The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is really beginning to heat up, and it’s offering investors......
(read more)
August 16 - News - Comments
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the......
(read more)
August 12 - News - Comments
Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc. (......
(read more)
August 7 - News - Comments
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), already quite expensive, spiked higher since takeover rumors surfaced in early July. But can a deal give......
(read more)
August 6 - News - Comments
In the last couple of months, we saw two big offers being made – and rejected – in the biotech sector. Both times, the companies that rejected......
(read more)
August 5 - News - Comments
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow. This cancer can lead to abnormally high calcium levels......
(read more)
July 26 - News - Comments
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout. Reportedly, four......
(read more)
July 24 - News - Comments
We have a bona fide biotech soap opera going on these days. Spurned love. Possible romance. Disgruntled suitor. And, of course, the unknown villain. In......
(read more)
July 24 - News - Comments
Global biotechnology industry revenue is expected to reach $262 billion this year showing growth of around 12.7% year over year. This industry has witnessed......
(read more)
July 22 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling......
(read more)
July 22 - News - Comments
In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company......
(read more)
July 19 - News - Comments
The “people familiar with the matter” are out in full force spouting off about who’s bidding for Onyx Pharmaceuticals, Inc. (NASDAQ......
(read more)
July 19 - News - Comments
Celgene Corporation (NASDAQ:CELG) has emerged as the leading treatment provider for blood cancer. The company value has almost doubled in the last year......
(read more)
July 19 - News - Comments
Celgene Corporation (NASDAQ:CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed......
(read more)
July 18 - News - Comments
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable......
(read more)
July 18 - News - Comments
Buyout! The word gets biotech investors’ blood flowing and their hearts racing. Mere rumors that a biotech stock could get bought out can send shares......
(read more)
July 17 - News - Comments
Good news seems to find its way to Celgene Corporation (NASDAQ:CELG)‘s door frequently these days. The company announced positive results today......
(read more)
July 11 - News - Comments
Recently Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) rejected a $10 billion takeover offer from Amgen, Inc. (NASDAQ:AMGN). However, after that it hired an......
(read more)
July 10 - News - Comments
Cancer-drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen, Inc. (NASDAQ:......
(read more)
July 10 - News - Comments